[1]
|
N. J. Vogelzang and W. M. Stadler, “Kidney Cancer,” Lancet, Vol. 352, No. 9141, 1998, pp. 1691-1696.
http://dx.doi.org/10.1016/S0140-6736(98)01041-1
|
[2]
|
B. Ljungberg, “Prognostic Factors in Renal Cell Carcinoma,” Scandinavian Journal of Surgery, Vol. 93, 2004, pp. 118-125.
|
[3]
|
S. Waalkes, A. J. Schrader and M. A. Kuczyk, “Current Treatment Options for Disseminated Renal Cell Carcinoma,” European Urology Supplements, Vol. 11, No. 3, 2012, pp. 73-78.
http://dx.doi.org/ 10.1016/j.eursup.2012.04.001
|
[4]
|
Y. G. Najjar and B. I. Rini, “Novel Agents in Renal Carcinoma: A Reality Check,” Therapeutic Advances in Medical, Vol. 4, No. 4, 2012, pp. 183-194.
http://dx.doi.org/10.1177/1758834012443725
|
[5]
|
B. Escudier, T. Eisen, W. M. Stadler, et al., “Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, 2007, pp. 125-134. http://dx.doi.org/10.1056/ NEJMoa060655
|
[6]
|
B. Escudier, T. Eisen, W. M. Stadler, et al., “Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial,” Journal of Clinical Oncology, Vol. 27, No. 20, 2009, pp. 3312-3318.
http://dx.doi.org/10.1200/ JCO.2008.19.5511
|
[7]
|
W. M. Stadler, R. A. Figlin, D. F. McDermott, et al., “Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America,” Cancer, Vol. 116, No. 5, 2010, pp. 1272-1280.
http://dx.doi.org/10.1002/cncr.24864
|
[8]
|
J. Beck, G. Procopio, E. Bajetta, et al., “Final Results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) Expanded-Access Study: A Large Open-Label Study in Diverse Community Settings,” Annals of Oncology, Vol. 22, No. 8, 2011, pp. 1812-1823.
http://dx.doi.org/10.1093/ annonc/mdq651
|
[9]
|
R. J. Motzer, T. E. Hutson, P. Tomczak, et al., “Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, 2007, pp. 115-124.
http://dx.doi.org/ 10.1056/NEJMoa065044
|
[10]
|
R. J. Motzer, T. E. Hutson, P. Tomczak, et al., “Overall Survival and Updated Results for Sunitinib Compared with Interferon Alfa in Patients with Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 27, No. 22, 2009, pp. 3584-3590.
http://dx.doi.org/10.1200/JCO.2008.20.1293
|
[11]
|
L. Gore, R. Bukowski and C. Porta, “Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (Mrcc)—Final Results,” Annals of Oncology, Vol. 23, 2012, p. 820.
|
[12]
|
B. Escudier, A. Pluzanska, P. Koralewski, et al., “Bevacizumab plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial,” Lancet, Vol. 370, No. 9605, 2007, pp. 2103-2111.
http://dx.doi.org/10.1016/S0140-6736(07)61904-7
|
[13]
|
B. Escudier, J. Bellmunt, S. Negrier, et al., “Phase III Trial of Bevacizumab plus Interferon Alfa-2a in Patients with Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival,” Journal of Clinical Oncology, Vol. 28, No. 13, 2010, pp. 2144-2150.
http://dx.doi.org/10.1200/JCO.2009.26.7849
|
[14]
|
B. I. Rini, S. Halabi, J. E. Rosenberg, et al., “Bevacizumab plus Interferon Alfa Compared with Interferon Alfa Monotherapy in Patients with Metastatic Renal Cell Carcinoma: CALGB 90206,” Journal of Clinical Oncology, Vol. 26, No. 33, 2008, pp. 5422-5428.
http://dx.doi.org/10.1200/JCO. 2008.16.9847
|
[15]
|
B. I. Rini, S. Halabi, J. E. Rosenberg, et al., “Phase III Trial of Bevacizumab plus Interferon Alfa versus Interferon Alfa Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206,” Journal of Clinical Oncology, Vol. 28, No. 13, 2010, pp. 2137-2143. http://dx.doi.org/ 10.1200/JCO.2009.26.5561
|
[16]
|
G. Hudes, M. Carducci, P. Tomczak, et al., “Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, 2007, pp. 2271-2281.
http://dx.doi.org/10.1056/NEJMoa066838
|
[17]
|
R. J. Motzer, B. Escudier, S. Oudard, et al., “Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial,” Lancet, Vol. 372, No. 9637, 2008, pp. 449-456.
http://dx.doi.org/10.1016/S0140-6736(08)61039-9
|
[18]
|
R. J. Motzer, B. Escudier, S. Oudard, et al., “Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors,” Cancer, Vol. 116, No. 18, 2010, pp. 4256-4265.
http://dx.doi.org/10.1002/cncr.25219
|
[19]
|
C. N. Sternberg, I. D. Davis, J. Mardiak, et al., “Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial,” Journal of Clinical Oncology, Vol. 28, No. 6, 2010, pp. 1061-1068. http://dx.doi.org/10.1200/JCO.2009.23.9764
|
[20]
|
C. N. Sternberg, R. E. Hawkins, J. Wagstaff, et al., “A Randomised, Double-Blind Phase III Study of Pazopanib in Patients with Advanced and/or Metastatic Renal Cell Carcinoma: Final Overall Survival Results and Safety Update,” European Journal of Cancer, Vol. 49, No. 6, 2013, pp. 1287-1296.
http://dx.doi.org/10.1016/j.ejca.2012.12.010
|
[21]
|
R. Motzer, T. E. Hutson and J. Reeves, “Randomized, Open Label, Phase III Trial of Pazopanib versus Sunitinib in First-Line Treatment of Patients with Metastatic Renal Cell Carcinoma (mRCC): Results of the COMPARZ Trial,” Annals of Oncology, Vol. 23, 2012, Article ID: LBA8.
|
[22]
|
B. I. Rini, B. Escudier, P. Tomczak, et al., “Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial,” Lancet, Vol. 378, No. 9807, 2011, pp. 1931-1939.
http://dx.doi.org/10.1016/S0140-6736(11)61613-9
|
[23]
|
R. Motzer, B. Escudier and P. Tomczak, “Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors,” Annals of Oncology, Vol. 23, 2012.
|
[24]
|
R. J. Motzer, B. Escudier, P. Tomczak, et al., “Axitinib versus Sorafenib as Second-Line Treatment for Advanced Renal Cell Carcinoma: Overall Survival Analysis and Updated Results from a Randomised Phase 3 Trial,” Lancet Oncology, Vol. 14, No. 6, 2013, pp. 552-562.
http://dx.doi.org/10.1016/S1470-2045(13)70093-7
|
[25]
|
R. J. Motzer, T. E. Hutson, M. R. Olsen, et al., “Randomized Phase II Trial of Sunitinib on an Intermittent versus Continuous Dosing Schedule as First-Line Therapy for Advanced Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 30, No. 12, 2012, pp. 1371-1377.
http://dx.doi.org/ 10.1200/JCO.2011.36.4133
|
[26]
|
B. Rini, C. Szczylik, N. M. Tannir, et al., “AMG 386 in Combination with Sorafenib in Patients with Metastatic Clear Cell Carcinoma of the Kidney: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study,” Cancer, Vol. 118, No. 24, 2012, pp. 6152-6161.
http://dx.doi.org/ 10.1002/cncr.27632
|
[27]
|
R. Motzer, D. Nosov and T. Eisen, “Tivozanib versus Sorafenib as Initial Targeted Therapy for Patients with Advanced Renal Cell Carcinoma: Results from a Phase III Randomized, Open-Label, Multicenter Trial,” Journal of Clinical Oncology, Vol. 30, 2012.
|
[28]
|
T. E. Hutson, D. Nosov and T. Eisen, “Subgroup Analyses of a Phase III Trial Comparing Tivozanib Hydrochloride versus Sorafenib as Initial Targeted Therapy for Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC),” Journal of Clinical Oncology, Vol. 31, 2013.
|
[29]
|
R. Motzer, T. Eisen and T. E. Hutson, “Overall Survival Results from a Phase III Study of Tivozanib Hydrochloride versus Sorafenib in Patients with Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 31, 2013.
|
[30]
|
T. E. Hutson, J. Gallardo and V. Lesovoy, “Axitinib versus Sorafenib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC),” Journal of Clinical Oncology, Vol. 31, 2013.
|
[31]
|
B. Rini, J. Bellmunt and J. Clancy, “Randomized Phase IIIb Trial of Temsirolimus and Bevacizumab versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from INTORACT,” ESMO, 2012, Article ID: LBA1487.
|
[32]
|
T. E. Hutson, B. Escudier and E. Esteban, “Temsirolimus vs Sorafenib as Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the INTORSECT Trial,” Annals of Oncology, Vol. 23, 2012, Article ID: LBA22.
|
[33]
|
B. Escudier, C. Szczylik, T. E. Hutson, et al., “Randomized Phase II Trial of First-Line Treatment with Sorafenib versus Interferon Alfa-2a in Patients with Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 27, No. 8, 2009, pp. 1280-1289.
http://dx.doi.org/10.1200/JCO.2008.19.3342
|
[34]
|
G. Procopio, E. Verzoni and F. de Braud, “Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma,” Oncology, Vol. 84, No. 1, 2013, pp. 39-42. http://dx.doi.org/10.1159/000342768
|
[35]
|
M. P. Sablin, S. Negrier, A. Ravaud, et al., “Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma,” Journal of Urology, Vol. 182, 2009, pp. 29-34.
http://dx.doi.org/10.1016/j.juro. 2009.02.119
|
[36]
|
V. Grunwald, C. Seidel, M. Fenner, et al., “Treatment of Everolimus-Resistant Metastatic Renal Cell Carcinoma with VEGF-Targeted Therapies,” British Journal of Cancer, Vol. 105, 2011, pp. 1635-1639.
http://dx.doi.org/10.1038/bjc.2011.389
|
[37]
|
N. Calvani, F. Morelli, S. Leo, et al., “Sequential Use of Sorafenib and Sunitinib in Advanced Renal Cell Carcinoma: Does the Order of Sequencing Matter?” Medical Oncology, Vol. 29, No. 3, 2012, pp. 1908-1913.
http://dx.doi.org/10.1007/s12032-011-0048-0
|
[38]
|
F. Stenner, R. Chastonay, H. Liewen, et al., “A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma,” Oncology, Vol. 82, 2012, pp. 333-340.
http://dx.doi.org/10.1159/000338001
|
[39]
|
A. Ambring, I. Bjorholt, E. Lesen, et al., “Treatment with Sorafenib and Sunitinib in Renal Cell Cancer: A Swedish Register-Based Study,” Medical Oncology, Vol. 30, 2013, p. 331. http://dx.doi.org/ 10.1007/s12032-012-0331-8
|
[40]
|
C. Porta, G. Procopio, G. Carteni, et al., “Sequential Use of Sorafenib and Sunitinib in Advanced Renal-Cell Carcinoma (RCC): An Italian Multicentre Retrospective Analysis of 189 Patient Cases,” BJU Internatioanl, Vol. 108, No. 8b, 2011, pp. E250-E257.
http://dx.doi.org/10.1111/j.1464-410X.2011.10186.x
|
[41]
|
B. Ljungberg, K. Bensalah and A. Bex, “Guidelines on Renal Cell Carcinoma,” European Association of Urology, 2013.
|
[42]
|
SWITCH-I: Sequential Study to Treat Renal Cell Carcinoma. http://clinicaltrials.gov/ct2/show/NCT00732914?term=NCT00732914&rank=1
|